Lupin receives approval from USFDA for Penicillamine Tablets USP

▴ Lupin receives approval from USFDA for Penicillamine Tablets USP
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis

Pharma major Lupin Limited announced that it has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP (RLD: Depen) had an annual sales of approximately USD 4 million in the U.S. (IQVIA MAT September 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Tags : #LupinLimited #LatestNewsonLupinLimited1stNov #LatestUSFDAApproval1stDec #LatestPharmaNews1stDec #RheumatoidArthritis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Parental tips for keeping teens safe onlineFebruary 08, 2023
The Symptoms and Causes of Anorexia NervosaFebruary 08, 2023
Pervez Musharraf President of Pakistan died of Amyloidosis, a rare diseaseFebruary 07, 2023
National AIDS Control Program – Importance of knowing HIV statusFebruary 06, 2023
FGM : Let's End the practice that hurts girls and womenFebruary 06, 2023
World Cancer Day - Most prominent cancers of IndiaFebruary 04, 2023
World Cancer Day - Never Give up the HopeFebruary 04, 2023
Salt - Effects of Consuming too much SaltFebruary 03, 2023
India’s mission of eliminating dog-mediated rabies by 2030February 03, 2023
Climate change and healthFebruary 02, 2023
Rheumatoid Arthritis Awareness Day: Let's Create AwarenessFebruary 02, 2023
Importance of early diagnosis and cancer screeningFebruary 01, 2023
Union Budget 2023-2024: What's for Healthcare?February 01, 2023
Nourish You has raised $2million to Invest in R&D and Strengthen its Market Presence.February 01, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
World Leprosy Day 2023 – Act now, End LeprosyJanuary 30, 2023
The Warrior Expedition 32/26: A Mission to Encourage Youths to join Indian ForcesJanuary 30, 2023
Mental health – What’s normal and what’s abnormalJanuary 30, 2023
Big Data in Healthcare and Its BenefitsJanuary 27, 2023